PeptideFactSheetsAn independent reference
Menu

Research peptide blend · Fact sheet

Modified GRF + ipamorelin

Also known as CJC no-DAC + ipamorelin · Mod GRF/IPA blend

Modified GRF + ipamorelin combines modified GRF (1–29) and ipamorelin. Human evidence for the exact blend is not established; studies of individual ingredients do not validate the mixture.

Not FDA approvedLimited or unclear evidence
Hormones & sexual healthMuscle & recovery

What is Modified GRF + ipamorelin?

modified GRF (1–29) and ipamorelin are discussed together under this name. Ratios, salts and formulations can differ between products.

No-DAC material differs from albumin-binding CJC-1295. The blend should not inherit the DAC half-life or study regimen.

Benefits & claims

Interest centers on stimulating growth-hormone release through two signaling pathways.

What the evidence supports

  • Human ipamorelin infusion research measured growth-hormone responses, not improved recovery from this blend.
  • Long-acting CJC-1295 trials evaluated the albumin-binding DAC molecule rather than the no-DAC ingredient.
  • Mechanistic complementarity does not demonstrate clinical synergy, better sleep or improved strength.
Research areas
  • Interest centers on stimulating growth-hormone release through two signaling pathways.

Dosage & frequency

No established human regimen

The reviewed sources do not establish a human treatment amount or frequency for Modified GRF + ipamorelin. Animal and laboratory exposures are not human regimens.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • No-DAC material differs from albumin-binding CJC-1295. The blend should not inherit the DAC half-life or study regimen.
  • No published ingredient regimen can be assembled into a supported regimen for this combination.

Interactions & precautions

  • The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.

What is still unresolved

  • Human efficacy and adverse-event rates for the exact formulation
  • Chemical compatibility, stability and ingredient identity
  • Whether combined effects differ from the ingredients alone
Ipamorelin human hormone-response study Long-acting CJC-1295 trial FDA: safety concerns for nominated bulk substances

Side effects & risks

  • FDA identifies important peptide-quality and immune-reaction concerns and serious events in a different intravenous ipamorelin setting.
  • Combined effects on hormone exposure and glucose handling require direct evaluation.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Limited or unclear evidence

The reviewed sources do not establish efficacy or a human regimen for this exact combination. Ingredient-only experiments cannot show that the mixture is effective, synergistic or safer.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

No attributable personal accounts were found in the sources reviewed.

Approval status

There is no FDA-approved Modified GRF + ipamorelin product or established approved use for this combination. Ingredient approvals, where present, do not transfer to the blend.

No FDA-approved product for this entry

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Human efficacy and adverse-event rates for the exact formulation
  • Chemical compatibility, stability and ingredient identity
  • Whether combined effects differ from the ingredients alone

Summary

Mechanistic complementarity does not demonstrate clinical synergy, better sleep or improved strength.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedIpamorelin human hormone-response study

    Single-agent infusion research, not blend efficacy.

  2. pubmedLong-acting CJC-1295 trial

    DAC molecule only; not evidence for a no-DAC combination.

  3. fdaFDA: safety concerns for nominated bulk substances

    Ingredient-specific uncertainties; compounding consideration is separate from FDA drug approval.

How we assess sources · Suggest a correction